The AGM presentation was excellent and very compelling. The...

The AGM presentation was excellent and very compelling. The technology and its transformation of the detection and treatment of cancer is unquestionable. The AGM and the associated presentation was in effect preaching to the converted. The shareholders know the value and the importance of the technology. Carl Zeiss and the Clermont Group Singapore know the significance of Optiscan's technology. Moreover, the Clermont Group has a 100 year history of building businesses of the future.

However, the general population does not know about the technology. This technology is very much in the public interest and should already be available in the treatment and detection of cancer. Well it is for brain cancer through Carl Zeiss Convivo - the digital biopsy tool.

However, the Optiscan InVivage Clinical Device is not yet available for the treatment and detection of other cancers.
Significantly, the InVivage should be as soon a possible available in the treatment of breast cancer.

However, the Breast Cancer organisations in Australia and breast cancer patients have no idea about Optiscan. Breast Cancer patients who are informed about the Optiscan technology question why is there no public knowledge about this technology. We all know someone who has or had breast cancer. When the public has knowledge of the technology they want it!

In addition, a lot of the posts and company releases are pitched to an audience that already has an understanding of the technology. For example references to 510(K) are made without explaining what it means. Accordingly, the post or the market release is not properly comprehended by the general public. And as discussed previously many medical professionals have no knowledge about Optiscan's technology. Following on, cancer patients are not being informed about the future technology. For example, a patient that requires cancer surgery may delay that surgery for 6 months upon the knowledge that the InVivage would be available.

Public knowledge and pressure is going to enliven Optiscan's technology and that is why we need a grass roots public information campaign about the technology. Perhaps a full page of a newspaper. Perhaps media releases that the media and public can understand in simple terms.

In conclusion, I suggest that Optiscan engages a cheap and effective media education campaign. It says it all when you contact a Breast Cancer organisation/s in Australia and they have absolutely no knowledge of Optiscan.

I will be sending a copy of this post to the Board of Optiscan for their consideration. It is time to move on from the past and advance this technology in a smart and efficient way. Should us shareholders fund a public education and information campaign as well? I would contribute. Alternatively, the Optiscan should recognise their shareholders as a resource that can be used to help grow the Optiscan technology. The shareholders need to engage in more action than talk. The delay of the InVivage is impacting on lives and the cost of health care in Australia and elsewhere.